- Home
- AMPL vs VRDN Comparison
AMPL vs VRDN Comparison
Compare AMPL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPL
- VRDN
- Stock Information
- Founded
- AMPL 2012
- VRDN 2006
- Country
- AMPL United States
- VRDN United States
- Employees
- AMPL N/A
- VRDN N/A
- Industry
- AMPL EDP Services
- VRDN Medical Specialities
- Sector
- AMPL Technology
- VRDN Health Care
- Exchange
- AMPL Nasdaq
- VRDN Nasdaq
- Market Cap
- AMPL 1.4B
- VRDN 1.6B
- IPO Year
- AMPL 2021
- VRDN N/A
- Fundamental
- Price
- AMPL $11.83
- VRDN $19.70
- Analyst Decision
- AMPL Hold
- VRDN Strong Buy
- Analyst Count
- AMPL 7
- VRDN 11
- Target Price
- AMPL $11.00
- VRDN $37.63
- AVG Volume (30 Days)
- AMPL 370.7K
- VRDN 1.4M
- Earning Date
- AMPL 11-07-2024
- VRDN 11-12-2024
- Dividend Yield
- AMPL N/A
- VRDN N/A
- EPS Growth
- AMPL N/A
- VRDN N/A
- EPS
- AMPL N/A
- VRDN N/A
- Revenue
- AMPL $292,544,000.00
- VRDN $302,000.00
- Revenue This Year
- AMPL $9.96
- VRDN $2.55
- Revenue Next Year
- AMPL $7.75
- VRDN N/A
- P/E Ratio
- AMPL N/A
- VRDN N/A
- Revenue Growth
- AMPL 8.29
- VRDN N/A
- 52 Week Low
- AMPL $7.37
- VRDN $11.40
- 52 Week High
- AMPL $14.42
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- AMPL 64.68
- VRDN 49.14
- Support Level
- AMPL $11.41
- VRDN $20.06
- Resistance Level
- AMPL $11.91
- VRDN $23.65
- Average True Range (ATR)
- AMPL 0.42
- VRDN 1.05
- MACD
- AMPL 0.02
- VRDN 0.16
- Stochastic Oscillator
- AMPL 77.72
- VRDN 49.45
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.